Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.
Adi MorScott FriedmanSharon HashmueliAmnon PeledMassimo PinzaniMatthew FrankelRifaat SafadiPublished in: Drug safety (2024)
NCT06025851, NCT06037577, and NCT06044467. Date of registration: September 2023.